Zai LabZLAB +0.99%64 EV-to-EBITDA is -10.56 as of Jul. 02, 2026. GuruFocus rates ZLAB with a GF Score™ of 64/100 and a GF Value™ of $30.27 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 396 Biotechnology companies, Zai Lab ranks worse than 252525% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Zai Lab's enterprise value is $1,673.6 Mil.
Zai Lab's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-158.4 Mil. Therefore, Zai Lab's EV-to-EBITDA for today is -10.56.
The historical rank and industry rank for Zai Lab's EV-to-EBITDA or its related term are showing as below:
ZLAB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -56.33 Med: -10.7 Max: -2.1
Current: -10.56
During the past 11 years, the highest EV-to-EBITDA of Zai Lab was -2.10. The lowest was -56.33. And the median was -10.70.
ZLAB's EV-to-EBITDA is ranked worse than 100% of 396
companies
in the Biotechnology industry
Industry Median: 13.045
vs ZLAB: -10.56
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-02), Zai Lab's stock price is $19.35.
Zai Lab's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.700. Therefore, Zai Lab's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Zai Lab (NAS:ZLAB) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zai Lab's share price for today is $19.35.
Zai Lab's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Zai Lab's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zai Lab's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zai Lab EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zai Lab's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Zai Lab's EV-to-EBITDA falls into.
Zai Lab's current Enterprise Value is $1,673.6 Mil.
Zai Lab's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-158.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab (ZLAB) has a EV-to-EBITDA of -10.56 as of Jul. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Zai Lab. According to the industry distribution chart, Zai Lab ranks #999999 out of 396 companies in the Biotechnology industry.
Is Zai Lab's EV-to-EBITDA too high?
Zai Lab's current EV-to-EBITDA is -10.56. Based on the distribution chart, Zai Lab ranks #999999 out of 396 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zai Lab has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's EV-to-EBITDA compare to STOK and ADMA?
According to the Biotechnology industry distribution chart, Zai Lab ranks #999999 out of 396 companies for EV-to-EBITDA. This places Zai Lab in the lower half of its industry. The industry median EV-to-EBITDA is 13.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.05, based on 396 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Zai Lab. For the Biotechnology industry, the median EV-to-EBITDA is 13.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zai Lab's current EV-to-EBITDA is -10.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (ZLAB) is currently considered Possible Value Trap. The stock's GF Value™ is $30.27, compared to a current price of $19.35 — trading 36.1% below its estimated fair value. The current EV-to-EBITDA is -10.56. Zai Lab's overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Zai Lab (ZLAB), the current EV-to-EBITDA is -10.56 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zai Lab (ZLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued.
The current stock price of $19.35 is trading 36.1% below its estimated GF Value™ of $30.27.
GuruFocus considers Zai Lab to be Possible Value Trap.
Key valuation signals for ZLAB:
EV-to-EBITDA: -10.56
GF Value™: $30.27 vs. price of $19.35 (36.1% below fair value)
No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score
Get the complete analysis for ZLAB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLAB has been successfully added to your 
